2nd generation CD40L blocker safely reduces new brain lesion

2nd generation CD40L blocker safely reduces new brain lesions in Phase 2 trial | Frexalimab may help reduce MS activity with fewer side effects: Trial data

Frexalimab, a second-generation CD40L blocker, safely reduced the number of new active brain lesions in relapsing MS patients in a Phase 2 trial.

Related Keywords

Colorado , United States , Erik Wallstr , Gavin Giovannoni , Consortium Of Multiple Sclerosis Center , London School Of Medicine , Queen Mary University Of London , Relapsing Multiple Sclerosis , Randomized Controlled Phase , Multiple Sclerosis Center , London School , Queen Mary University ,